Bettina M. Cockroft - Nov 17, 2025 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Role
Director
Signature
/s/ Christopher Downs, Attorney-in-fact
Stock symbol
CNSP
Transactions as of
Nov 17, 2025
Transactions value $
$0
Form type
4
Date filed
11/19/2025, 05:00 PM
Previous filing
Jun 9, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cockroft Bettina M. Director C/O CNS PHARMACEUTICALS, INC, 100 WEST LOOP SOUTH, SUITE 900, HOUSTON /s/ Christopher Downs, Attorney-in-fact 2025-11-19 0001900452

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNSP Option to purchase common stock Award $0 +1.52K $0.00 1.52K Nov 17, 2025 Common Stock 1.52K $12.48 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").
F2 The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.
F3 Issued in connection with the reporting person's employment with the Company.